Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of VLPM01 Malaria Vaccine with CHMI
NCT03867331Phase 1Completed
- Sponsor
- VLP Therapeutics
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of VLPM-01 in malaria (4 arms), sponsored by VLP Therapeutics. Primary endpoints: Occurrence of solicited local reactogenicity, Occurrence of solicited systemic reactogenicity and 3 more. Started Mar 2019; status: completed.
02
Drugs
VLPM-01
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03867331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867331.